The proteasome: a suitable antineoplastic target

By J. Adams. Nature Reviews. Cancer, 2004

1,235 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/684e4f35b69333157ab08fac47d2b173eaf8de5c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. S. Lecker
2. A. Goldberg
3. W. Mitch
4. P. Richardson
5. T. Hideshima
6. A. Kinghorn
7. Stephen W. Fesik
8. Masakazu Toi

In Oncology

1. A. Goldberg
2. A. Kinghorn
3. Stephen W. Fesik
4. Masakazu Toi
5. A. Letai
6. Marcy J. Balunas
7. Chikashi Nakanishi
8. J. Adams

Citations in the corpus

• Drug discovery from medicinal plants. (2005, methodology): “…at UIC, as well as panels of diverse mechanistic and cell-based assays at RTI and BMS. Examples of mechanism-based assays include a proteasome inhibition assay (Almond and Cohen, 2002; Adams, 2004) and a histone deacetylase (HDAC) inhibition assay (Johnstone, 2002; Villar-Garea and Esteller, 2004).”
• Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. (2007, methodology): “Inhibition of the proteasome results in the accumulation of these substrate proteins and leads to cell death (4).”
• Promoting apoptosis as a strategy for cancer drug discovery (2005, background): “The proteasome could also be considered as a target for inducing apoptosis, and proteasome inhibitors are being used to treat cance”
• Nuclear factor-κB inhibitors as sensitizers to anticancer drugs (2005, background): “Other explanations for the anticancer activity of proteasome inhibitors include the inhibition of IκB degradation, which leads to the maintenance of NF-κB in the cytoplas”
• Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives (2011, background): “The 26S proteasome contains the 20S proteasome that serves as the catalytic core and two 19S regulatory subunits, which act as a recognition and entry site for proteins destined for proteolysis [1, 24].”
• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. (2005, background): “NPI-0052 is structurally distinct from Bortezomib and inhibits all three protease activities within the proteasome both in vitro and in vivo The naturally occurring and synthetic inhibitors of the ubiquitinproteasome pathway include peptide aldehydes, peptide boronates, nonpeptide inhibitors, peptid”
• Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. (2006, background): “With the backing of the National Cancer Institute, these agents went into human trials against various cancers, and the special sensitivity of myeloma cells became evident in phase I trials (52).”